List view / Grid view
A new biodegradable gel can release drugs and special antibodies that simultaneously deplete macrophages from the surgical site and activate T cells.
A new study from the University of Michigan Rogel Cancer Center, US has revealed that a cytokine and a fatty acid can work together to trigger ferroptosis. Here, Dr Weiping Zou, the lead researcher from the study, outlines how this process could be used to target cancer cells and enhance immunotherapies.
The new nanotechnology left six of 10 mice with lymphoma tumour-free and was effective in melanoma when combined with existing drugs.
Activating the protein channel TRPML1 induced selective melanoma cell death while sparing normal cells, suggesting a potential pathway for new cancer therapies.
A nanotherapeutic delivery system displayed high efficacy against metastatic tumours in mice, potentially improving chemotherapy treatments.
New research found mutations that cause melanoma result from a chemical conversion in DNA fuelled by sunlight, undermining previous theories.
Researchers have shown that natural killer cell immunotherapy effectively treated mice harbouring human melanoma tumours.
Researchers say that inhibiting NLRP3 with Dapansutrile could be an effective strategy to prevent melanoma tumour growth.
A combination of checkpoint and small molecule inhibitors showed success at targeting Myc oncogenes in mouse neuroblastoma and melanoma models.
Vito Quaranta, professor of biochemistry and pharmacology, discusses how cancerous cells adopting novel mechanisms of energy production could be sensitised to existing therapies with a focus on melanoma.
Researchers have discovered that in mice with cancers in the liver, immunotherapy and radiotherapy prevented T-cell death.
Immunology study shows that NF-kappa B-inducing kinase (NIK) is critical to T cell metabolism and the antitumour immune response.
The Junior Editors of Drug Target Review, Victoria Rees and Hannah Balfour, discuss some of the most noteworthy news and announcements from this year.
Scientists have shown that age may cause genetically identical melanoma skin cancer cells to respond differently to treatment, making age a primary factor in treatment response.